BioLife Solutions, Inc. reaffirmed earnings guidance for the fiscal 2023. For the period, the company expected revenue to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.43 USD | +4.54% |
|
+2.05% | +31.88% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.88% | 99Cr | |
-5.60% | 18TCr | |
-4.45% | 10TCr | |
-4.15% | 6.75TCr | |
-8.63% | 4.51TCr | |
+9.70% | 4.44TCr | |
+6.13% | 4.07TCr | |
+15.22% | 2.98TCr | |
+14.80% | 2.45TCr | |
-6.46% | 2.4TCr |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023